The role of chronic inflammation and Leu55Met PON1 polymorphism in the pathogenesis of polycystic ovary syndrome

Gynecological Endocrinology

Volumn 26, Issue 9, 2010, Pages 673-683

  Lenarcik, Agnieszka ^a   Bidzińska Speichert, Bozena ^a   Tworowska Bardzińska, Urszula ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

inflammation; Leu55Met PON1 polymorphism; PCOS

Indexed keywords

ANDROSTENEDIONE; ARYLDIALKYLPHOSPHATASE 1; C REACTIVE PROTEIN; FIBRINOGEN; FOLLITROPIN; GLUCOSE; INSULIN; LIPID; LUTEINIZING HORMONE; PRASTERONE SULFATE; TESTOSTERONE;

ADULT; ANDROGEN BLOOD LEVEL; ANDROSTENEDIONE BLOOD LEVEL; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY HEIGHT; BODY MASS; CHRONIC INFLAMMATION; CONTROLLED STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLITROPIN BLOOD LEVEL; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERANDROGENISM; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LEUKOCYTE COUNT; LIPID BLOOD LEVEL; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

ADULT; AMINO ACID SUBSTITUTION; ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; CHRONIC DISEASE; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INFLAMMATION; INSULIN RESISTANCE; LEUCINE; METHIONINE; POLYCYSTIC OVARY SYNDROME; POLYMORPHISM, SINGLE NUCLEOTIDE; TESTOSTERONE; YOUNG ADULT;

EID: 77955818260     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513591003686387     Document Type: Article

References (73)

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-2749.
2. Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004;18:671-683.
3. Barnes RB, Rosenfield RL, Burstein S, Ehrmann DA. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med 1989;320:559-565.
4. Gilling-Smith C, Story H, Rogers V, Franks S. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1997;47:93-99.
5. Yen SS, Vela P, Rankin J. Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease. J Clin Endocrinol Metab 1970;30:435-442.
6. Book CB, Dunaif A. Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1999;84:3110-3116. (Pubitemid 30646930)
7. Dunaif A, Xia J, Book CB, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995;96:801-810.
8. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999;20:535-582.
9. Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, Blumenfeld Z. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004;89:2160-2165.
10. Kelly CCJ, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001;86:2453-2455.
11. Orio F Jr, Palomba S, Cascella T, Di Biase S, Manguso F, Tauchmanova L, Nardo LG, Labella D, Savastano S, Russo T, et al. The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:2-5.
12. Talbott EO, Zborowski JV, Boudreaux MY, McHugh-Pemu KP, Sutton-Tyrrell K, Guzick DS. The Relationship between C-reactive protein and carotid intima-media wall thickness in middle-aged women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:6061-6067.
13. Tarkun I, Arslan BC, Cantürk Z, Türemen E, Sahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin EndocrinolMetab 2004;89:5592-5596.
14. American Association of Clinical Endocrinologists Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome. American association of clinical endocrinologists polycystic ovary syndrome writing committee. Endocr Pract 2005;11:126-134.
15. Carmina E, Lobo RA. Polycystic Ovary Syndrome (PCOS): Arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999;84:1897-1899.
16. Dokras A, Bochner M, Hollinrake E, Markham S, Vanvoorhis B, Jagasia DH. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 2005; 106:131-137.
17. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:48-53. (Pubitemid 43069116)
18. Glueck CJ, Wang P, Kobayashi S, Phillips H, Sieve-Smith L. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 2002;77:520-525.
19. Atiomo WU, Bates SA, Condon JE, Shaw S, West JH, Prentice AG. The plasminogen activator system in women with polycystic ovary syndrome. Fertil Steril 1998;69:236-241.
20. Benson S, Janssen OE, Hahn S, Tan S, Dietz T, Mann K, Pleger K, Schedlowski M, Arck PC, Elsenbruch S. Obesity, depression, and chronic low-grade inflammation in women with polycystic ovary syndrome. Brain Behav Immun 2008;22:177-184.
21. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800.
22. Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril 2003;80:123-127.
23. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:863-1861
24. Giallauria F, Palomba S, Manguso F, Vitelli A, Maresca L, Tafuri D, Lombardi G, Colao A, Vigorito C, Orio F. Abnormal heart rate recovery after maximal cardiopulmonary exercise stress testing in young overweight women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007; 68:88-93.
25. Glueck CJ, Wang P, Fontaine RN, Sieve-Smith L, Tracy T, Moore SK. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism 1999;48:1589-1595.
26. La Du BN, Adkins S, Kuo CL, Lipsig D. Studies on human serum paraoxonase/arylesterase. Chem Biol Interact 1993;87:25-34.
27. Mackness MI, Harty D, Bhatnagar PH, Winocour S, Arrol M, Ishola M, Durrington PN. Serum paraoxonase activity in familial hypercholesterolaemia and insulindependent diabetes mellitus. Atherosclerosis 1991;86:193-199.
28. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:473-480.
29. La Du BN, Billecke S, Hsu C, Haley RW, Broomfield CA. Serum paraoxonase (PON1) isozymes: the quantitative analysis of isozymes affecting individual sensitivity to environmental chemicals. Drug Metab Dispos 2001;29:566-569.
30. van Himbergen TM, van Tits LJ, Roest M, Stalenhoef AF. The story of PON1: how an organophosphate-hydrolysing enzyme is becoming a player in cardiovascular medicine. Neth J Med 2006;64:34-38.
31. Isik B, Ceylan A, Isik R. Oxidative stress in smokers and nonsmokers. Inhal Toxicol 2007;19:767-769.
32. Rantala M, Silaste ML, Tuominen A, Kaikkonen J, Salonen JT, Alfthan G. Dietary modifications and gene polymorphisms alter serum paraoxonase activity in healthy women. J Nutr 2002;132:3012-3017.
33. Rao MN, Marmillot P, Gong M, Palmer DA, Seeff LB, Strader DB. Light, but not heavy alcohol drinking, stimulates paraoxonase by upregulating liver mRNA in rats and humans. Metabolism 2003;52:1287-1294.
34. San Millán JL, Cortón M, Villuendas G, Sancho J, Peral B, Escobar-Morreale HF. Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. J Clin Endocrinol Metabol 2004;89:2640-2646.
35. McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem 1986;32:671-673.
36. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995;15:1812-1818.
37. Dursun P, DemirtaşE, Bayrak A, Yarali H. Decreased serum paraoxonase 1 (PON1) activity: an additional risk factor for atherosclerotic heart disease in patients with PCOS? Hum Reprod 2006;21:104-108.
38. Fenkci IV, Serteser M, Fenkci S, Kose S. Paraoxonase levels in women with polycystic ovary syndrome. J Reprod Med 2007;52:879-883.
39. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
40. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-1447.
41. Matthews DR, Hosker JP, Rudenski AS. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;42:678-687.
42. Ducan MH, Singh BM, Wise PH, Carter G. Alaghband-Zadeh J. A simple measure of insulin resistance. Lancet 1995;346:120-121.
43. Katz A, Nambi SS, Mather K. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85: 2402-2410.
44. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-1470.
45. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-a in human obesity and insulin resistance. J Clin Invest 1995;95:2409-2415.
46. Hak AE, Pols HA, Stehouwer CD, Meijer J, Kiliaan AJ, Hofman A, Breteler MM, Witteman JC. Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in non-diabetic elderly: the Rotterdam study. J Clin Endocrinol Metabol 2001;86:4398-4405.
47. Escobar-Morreale HF, Calvo RM, Villuendas G, Sancho J, San Millan JL. Association of polymorphisms in the interleukin 6 receptor complex with obesity and hyperandrogenism. Obes Res 2003;11:987-996.
48. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha-and obesity-induced insulin resistance. Science 1996;271:665-668.
49. Spaczynski RZ, Arici A, Duleba AJ. Tumor necrosis factor-a stimulates proliferation of rat ovarian theca-interstitial cells. Biol Reprod 1999;61:993-998.
50. Villuendas G, San Millan JL, Sancho J, Escobar-Morreale HF. The 597 G-A and 174 G-C polymorphisms in the promoter of the IL-6 gene are associated with hyperandrogenism. J Clin Endocrinol Metab 2002;87:1134-1141.
51. Möhlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer AF, Schill T, Schlösser HW, Brabant G, Schöfl C. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 2004; 150:525-532.
52. Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, Muller B. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab 2005;90:6014-6021.
53. Escobar-Morreale HF, Botella-Carretero JI, Villuendas G, Sancho J, San Millan JL. Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity. J Clin Endocrinol Metab 2004;89:806-811.
54. Rodin A, Thakkar H, Taylor N, Clayton R. Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase. N Engl J Med 1994;330:460-465.
55. Sayin NC, Gucer F, Balkanli-Kaplan P, Yuce MA, Ciftci S, Kucuk M, Yardim T. Elevated serum TNF-alpha in normal-weight women with polycystic ovaries or the polycystic ovary syndrome. J Reprod Med 2003;48:165-170.
56. Vgontzas AN, Trakada G, Bixler EO, Lin HM, Pejovic S, Zoumakis E, Chrousos GP, Legro RS. Plasma interleukin 6 levels are elevated in polycystic ovary syndrome independently of obesity or sleep apnea. Metabolism 2006;55:1076-1082.
57. Zhang YF, Yang YS, Hong J, Gu WQ, Shen CF, Xu M, Du PF, Li XY, Ning G. Elevated serum levels of interleukin-18 are associated with insulin resistance in women with polycystic ovary syndrome. Endocrine 2006;29:419-423.
58. Nasiek M, Kos-Kuda B, Ostrowska Z, Marek B, Kuda M, Siemiń ska L, Kajdaniuk D, Foltyn W, Zemczak A. Acute phase proteins: C-reactive protein and fibrinogen in young women with polycystic ovary syndrome. Pathophysiology 2007;14:23-28.
59. Diamanti-Kandarakis E, Alexandraki K, Piperi C, Protogerou A, Katsikis I, Greece Paterakis T, Lekakis J, Panidis D. Inflammatory and endothelial markers in women with polycystic ovary syndrome. Eur J Clin Invest 2006; 36:691-697. (Pubitemid 44393927)
60. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C, Aessopos A, Katsikis I, Katsilambros N, Kreatsas G, Panidis D. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 2006;21:1426-1431.
61. Guzelmeric K, Alkan N, Pirimoglu M, Unal O, Turan C. Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome. Gynecol Endocrinol 2007;23:505-510.
62. Lord J, Thomas R, Fox B, Acharya U, Wilkin T. The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome. BJOG 2006;113:1203-1209.
63. Vrbikova J, Bicikova M, Tallova J, Hill M, Starka L. Homocysteine and steroids levels in metformin treated women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2002;110:74-76.
64. Yarali H, Yildirir A, Aybar F, Kabakci G, Bukulmez O, Akgul E, Oto A. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril 2001;76:511-516.
65. Bickerton AS, Clark N, Meeking D, Shaw KM, Crook M, Lumb P, Turner C, Cummings MH. Cardiovascular risk in women with polycystic ovarian syndrome (PCOS). J Clin Pathol 2005;58:151-154.
66. Olszanecka-Glinianowicz M, Banaś M, Zahorska-Markiewicz B, Janowska J, Koceak P, Madej P, Klimek K. Is the polycystic ovary syndrome associated with chronic inflammation per se? Eur J Obstet Gynecol Reprod Biol 2007;133:97-202.
67. Shroff R, Kerchner A, Maifeld M, Van Beek EJ, Jagasia D, Dokras A. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. J Clin Endocrinol Metab 2007;92:4609-4614.
68. Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, Vidal H, Hainque B. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000; 85:3338-3342.
69. Zinman B, Hanley AJ, Harris SB, Kwan J, Fantus IG. Circulating tumor necrosis factor-a concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metabol 1999;84:272-278.
70. Gonzalez F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:336-340.
71. Mandrup-Poulsen T, Nerup J, Reimers JI, Pociot F, Andersen HU, Karlsen A, Bjerre U, Bergholdt R. Cytokines and the endocrine system I. The immunoendocrine network. Eur J Endocrinol 1995;133:660-671.
72. Arca M, Ombres D, Montali A, Campagna F, Mangieri E, Tanzilli G, Campa PP, Ricci G, Verna R Pannitteri G. PON1 L55M polymorphism is not a predictor of coronary atherosclerosis either alone or in combination with Q192R polymorphism in an Italian population. Eur J Clin Invest 2002;32:9-15.
73. Watzinger N, Schmidt H, Schumacher M, Schmidt R, Eber B, Fruhwald FM, Zweiker R, Kostner GM, Klein W. Human paraoxonase 1 gene polymorphisms and the risk of coronary heart disease: a community-based study. Cardiology 2002; 98:116-122.